|
|
 |
2008
Vafiadaki E, Arvanitis DA, Pagakis SN, Papalouka V, Sanoudou
D, Kontrogianni-Konstantopoulos A, Kranias EG.The Anti-apoptotic Protein
HAX-1 Interacts with SERCA2 and Regulates Its Protein Levels to Promote
Cell Survival.Mol Biol Cell. 2008 Oct 29. [Epub ahead of print]
Fan GC, Zhou X, Wang X, Song G, Qian J, Nicolaou P, Chen
G, Ren X, Kranias EG. Heat Shock Protein 20 Interacting With Phosphorylated
Akt Reduces Doxorubicin-Triggered Oxidative Stress and Cardiotoxicity.
Circ Res. 2008 Oct 30. [Epub ahead of print]
Nicolaou P, Knöll R, Haghighi K, Fan GC, Dorn GW 2nd,
Hasenfuß G, Kranias EG. A human mutation in the anti-apoptotic heat
shock protein 20 abrogates its cardioprotective effects. J Biol Chem.
2008 Sep 12. [Epub ahead of print]
Chen G, Zhou X, Pathak A, Dorn 2nd GW, Kranias EG. The Human
G147D-Protein Phosphatase 1 Inhibitor-1 Polymorphism Is Not Associated
with Altered Clinical Characteristics in Heart Failure. Cardiology. 2008
Aug 12;112(3):224-231.
Haghighi K, Chen G, Sato Y, Fan GC, He S, Kolokathis F,
Pater L, Paraskevaidis I, Jones WK, Dorn GW 2nd, Kremastinos DT, Kranias
EG. A human phospholamban promoter polymorphism in dilated cardiomyopathy
alters transcriptional regulation by glucocorticoids. Hum Mutat. 2008
May;29(5):640-7.
Fan GC, Yuan Q, Kranias EG. Regulatory roles of junctin
in sarcoplasmic reticulum calcium cycling and myocardial function.Trends
Cardiovasc Med. 2008 Jan;18(1):1-5.
Chen G, Zhou X, Nicolaou P, Rodriguez P, Song G, Mitton
B, Pathak A, Zachariah A, Fan GC, Dorn GW 2nd, Kranias EG. A human polymorphism
of protein phosphatase-1 inhibitor-1 is associated with attenuated contractile
response of cardiomyocytes to beta-adrenergic stimulation.FASEB J. 2008
Jun;22(6):1790-6.
Pattison JS, Waggoner JR, James J, Martin L, Gulick J, Osinska
H, Klevitsky R, Kranias EG, Robbins J. Phospholamban overexpression in
transgenic rabbits. Transgenic Res. 2008 Apr;17(2):157-70.
2007
Mohler PJ, Healy JA, Xue H, Puca AA, Kline CF, Allingham
RR, Kranias EG,Rockman HA, Bennett V. Ankyrin-B syndrome: enhanced cardiac
function balanced by risk of cardiac death and premature senescence. PLoS
ONE. 2007 Oct 17;2(10):e1051.
Arvanitis DA, Vafiadaki E, Fan GC, Mitton BA, Gregory KN,
Del Monte F, Kontrogianni-Konstantopoulos A, Sanoudou D, Kranias EG. Histidine-rich
Ca-binding protein interacts with sarcoplasmic reticulum Ca-ATPase. Am
J Physiol Heart Circ Physiol. 2007 Sep;293(3):H1581-9.
Zhou X, Fan GC, Ren X, Waggoner JR, Gregory KN, Chen G,
Jones WK, Kranias EG. Overexpression of histidine-rich Ca-binding protein
protects against ischemia/reperfusion-induced cardiac injury. Cardiovasc
Res. 2007 Aug 1;75(3):487-97.
Rodriguez P, Mitton B, Nicolaou P, Chen G, Kranias EG. Phosphorylation
of human inhibitor-1 at Ser67 and/or Thr75 attenuates stimulatory effects
of protein kinase A signaling in cardiac myocytes. Am J Physiol Heart
Circ Physiol. 2007 Jul;293(1):H762-9.
Pathak A, Baldwin B, Kranias EG. Key protein alterations
associated with hyperdynamic cardiac function: insights based on proteomic
analysis of the protein phosphatase 1 inhibitor-1 overexpressing hearts.
Hellenic J Cardiol. 2007 Jan-Feb;48(1):30-6.
Vafiadaki E, Sanoudou D, Arvanitis DA, Catino DH, Kranias
EG, Kontrogianni-Konstantopoulos A. Phospholamban interacts with HAX-1,
a mitochondrial protein with anti-apoptotic function. J Mol Biol. 2007
Mar 16;367(1):65-79.
Yuan Q, Fan GC, Dong M, Altschafl B, Diwan A, Ren X, Hahn
HH, Zhao W, Waggoner JR, Jones LR, Jones WK, Bers DM, Dorn GW 2nd, Wang
HS, Valdivia HH, Chu G, Kranias EG. Sarcoplasmic reticulum calcium overloading
in junctin deficiency enhances cardiac contractility but increases ventricular
automaticity. Circulation. 2007 Jan 23;115(3):300-9.
Vila-Petroff M, Salas MA, Said M, Valverde CA, Sapia L,
Portiansky E, Hajjar RJ, Kranias EG, Mundiña-Weilenmann C, Mattiazzi
A. CaMKII inhibition protects against necrosis and apoptosis in irreversible
ischemia-reperfusion injury. Cardiovasc Res. 2007 Mar 1;73(4):689-98.
Fan GC, Yuan Q, Zhao W, Chu G, Kranias EG. Junctin is a
prominent regulator of contractility in cardiomyocytes. Biochem Biophys
Res Commun. 2007 Jan 19;352(3):617-22.
2006
Ji, Y., Zhao, W., Li, B., DeSantiago,
J., Picht, E., Kaetzel, M., Schultz, J.J., Kranias, E.G., Bers, D.M.,
Dedman, J.R: Targeted inhibition of sarcoplasmic reticulum CaMKII activity
results in alterations of Ca2+ homeostasis and cardiac contractility.
Am
J Physiol Heart Circ Physiol. 2006 Feb;290(2):H599-606. Epub 2005 Sep
2.
Wu, Y., Shintani, A., Grueter, C.,
Zhang, R., Hou, Y., Yang, J., Kranias, E.G., Colbran, R.J., Anderson,
M.E.: Suppression of dynamic Ca2+ transient responses to pacing in ventricular
myocytes from mice with genetic Calmodulin kinase II inhibition. J
Mol Cell Cardiol. Feb;40(2):213-223. 2006.
Haghighi, K., Kolokathis, F., Gramolini,
A. O., Waggoner, J. R., Pater, L., Lynch, R.A., Fan, G.C., Tsiapras, D.,
Dorn, G.W., MacLennan, D.H., Kremastinos, D.K., Kranias, E.G.: A mutation
in the human phospholamban gene, deleting arginine14, results in lethal,
hereditary cardiomyopathy. Proc.
Natl. Acad. Sci. U S A. Jan 31;103(5):1388-93. 2006.
Gramolini, A.O., Trivieri, M.G.,
Oudit, G., Kislinger, T., Li, W., Patel, M., Kranias, E.G., Backx, P.H.,
MacLennan. D.H.: Cardiac-spefific Overexpression of Sarcolipin in Phospholamban
Null Mice Imparis Myocyte Function Which is Restored by Phosphorylation.
Proc
Natl Acad Sci U S A. 2006 Feb 14;103(7):2446-51.
Zhao, W., Yuan, Q., Pathak, A., Chu,
G., Mitton, B., Waggoner, J., Qian, J., Sun, X., Jin, J., Braz, J.C.,
Hahn, H.S., Marreez, Y., Syed, F., Pollesello, P., Annila, A., Brown,
K.M., Wang, H.S., Schultz, J.E., Molkentin, J.D., Liggett, S.T., Dorn,
G.W., Kranias, E.G.: The presence of Lys27 Instead of Asn27 in Human phospholamban
promotes SERCA2 Superinhibition and Cardiac Remodeling. Circulation.113:995-1004,
2006.
Valverde C.A,
Mundiña-Weilenmann C., Reyes M., Kranias E.G., Escobar A.L., Mattiazzi
A. Phospholamban Phosphorylation sites enhance the Recovery of Intracellular
Ca2+ After Perfusion Arrest in Isolated, Perfused Mouse Heart. Cardiovas.
Res. 2006 Mar 1; [Epub ahead of print].
Gregory, K.N., Ginsburg,
K.S., Bodi, I., Hahn, H., Marreez, Y.M., Song, Q., Padmanabhan, P.A.,
Mitton, B.A., Waggoner, J.R., del Monte, F., Park, W.J., Dorn, G.W., Bers,
D.M., Kranias, E.G.: Histidine-rich Ca binding protein: a regulator of
sarcoplasmic reticulum calcium sequestration and cardiac function. J
Mol Cell Cardiol. 2006 Apr 4; [Epub ahead of print].
Mattiazzi A., Mundiña-Weilenmann,
C., Vittone, L., Said, M., Kranias, E.G.: The importance of the Thr17
residue of phospholamban as a phosphorylation site under hysiological
and pathological conditions. Braz.
J. Med. Bio. Res. Braz J Med Biol Res. 2006 May;39(5):563-72. Epub 2006
Apr 20.
2005
Pathak, A., del Monte, F., Zhao,
W., Mitton, B., Carr, A., Shultz, J., Hahn, H., Syed, F., Bodi, I., Weiser,
D., Mavila, N., Jha, L., O'Neal, E., Qian, J., Fan, G., Marreez, Y., McGraw,
D.W., Heist, E.K., Guerrero, J.L., DePaoli-Roach, A.A., Hajjar, R.J.,
and Kranias, E.G.: Enhancement of cardiac function and suppression of
heart failure progression by inhibition of protein phosphatase 1 Circ.
Res 96:756-66, 2005.
Sanoudou, D., Vafiadaki, E., Arvanitis,
D.A., Kranias, E.G., Kontrogianni-Konstantopoulos, A.: Array lessons from
the heart: focus on the genome and transcriptome of cardiomyocytes. Physiological
Genomics 21:131-43, 2005.
Fan, G.C., Chu, G., Kranias, E.G.:
Hsp20 and its cardioprotection. Trends
Cardiovasc. Med. 15(4):138-47, 2005.
Rodriquez, P., Mitton, B., Kranias,
E.G.: Phosphorylation of glutathione-S-transferase by protein kinase C-a
implications for affinity-tag purification. Biotechnology
Lett. 27(23-24): 1869-73. 2005.
Mattiazzi A, Mundian-Weilenmann C,
Guoxiang C, Vittone L, Kranias E.: Role of phospholamban phosphorylation
on Thr (17) in cardiac physiological and pathological conditions. Cardiovasc
Res. (2005) 689, 366-375.
Ji, Y., Zhao,
W., Li, B., DeSantiago, J., Picht, E., Kaetzel, M., Schultz, J.J., Kranias,
E.G., Bers, D.M., Dedman, J.R.:Targeted inhibition
of sarcoplasmic reticulum CaMKII activity results
in alterations of Ca2+ homeostasis and cardiac contractility.
Am
J Physiol Heart Circ Physiol. 2005 Sep 2 [E-pub ahead of
print].
Sanoudou, D., Vafiadaki,
E., Arvanitis, D.A., Kranias, E, Kontrogianni-Konstantopoulos,
A.: Array lessons from the heart: focus on the
genome and transcriptome of cardiomyocytes. Physiological
Genomics 21:131-43, 2005.
Mundina-Weilenmann, C.,
Ferrero, P., Said, M., Vittone, L., Kranias, E.G., Mattiazzi, A.: Role
of phosphorylation of Thr17 residue of phospholamban in Mechanical
recovery during hypercapnic acidosis. Cardiovascular
Research 66: 114-122, 2005.
Pathak, A., del Monte,
F., Zhao, W., Mitton, B., Carr, A., Shultz,
J., Hahn, H., Syed, F., Bodi,
I., Weiser, D., Mavila, N., Jha, L., O’Neal, E., Qian, J., Fan,
G., Marreez, Y., McGraw, D.W., Heist, E.K.,
Guerrero, J.L., DePaoli-Roach, A.A., Hajjar, R.J., and Kranias, E.G. Enhancement of cardiac function
and suppression of heart failure progression by inhibition of protein
phosphatase 1. Circ.
Res 96:756-66, 2005.
Fan G.C., Ren X., Qian J. Yuan Q., Wang Y.,
Jones W.K., Chu G., and Kranias E.G.: A novel
cardioprotetive role of a small heat-shock protein Hsp20 against
ischemia/reperfusion injury. Circulation
111:1792-9, 2005
Invited Articles:
Mundina-Weilenmann C, Ferrero P,
Said M, Vittone L, Kranias EG, Mattiazzi A. Role of phosphorylation
of Thr(17) residue of phospholamban in mechanical recovery during hypercapnic
acidosis. Cardiovasc Res. 2005 Apr 1;66(1):114-22.
Fan, G.C., Chu, G. and Kranias, E.G.: Hsp20 and Its Cardioprotection.
Trends in Cardiov. Med 2005 May;15(4):138-41.
Waggoner J., and Kranias EG.: Role
of Phospholamban in the Pthogenesis of Heart Failure. Heart Failure Clinics.
July 2005 Vol. 1, Issue 2, 207-218.
2004
Sutliff, R.L., Conforti, L., Weber, C., Kranias, E.G., and Paul, R.J.: Regulation
of the spontaneous contractile activity of the portal vein by the sarcoplasmic
reticulum: Evidence from the phospholamban gene-ablated mouse. Vascular
Pharmacology 41: 197-204, 2004.
Szentesi, P., Pignier, C., Egger, M., Kranias, E.G., and Niggli E. Sarcoplamic reticulum
Ca2+ refilling controls recovery from refractoriness in heart muscle.
Circ.
Res. 95:807-813, 2004.
Chu, G., Kerr, J.P., Mitton, B., Egnaczyk, G.F., Vazquez,
J.A., Shen, M., Kilby,
G.W., Stevenson, T.I., Maggio, J.E., Vockley, G., Rapundalo, S.T., and
Kranias, E.G.:
Proteomic Analysis of hyperdynamic mouse
hearts with enhanced sarcoplasmic reticulum calcium cycling. FASEB J. 18(14): 1725-27, 2004.
Fan, G., Gregory, K.N.,
Zhao, W., Park, W.J., and Kranias, E.G.: Regulation of myocardial function
by histifine-rich, Ca2+ binding protein. Am.
J. Physiol, 287:H1 705-H1 711, 2004.
Zhao, W., Uehara, Y., Chu, G., Young, K., and
Kranias, E.G.: Threonine-17 phosphorylation of phospholamban: a key determinant
of cardiac force-frequency relationship. J.
Mol. Cell. Cardiol. 37:602-12, 2004.
Fan, G.C., Chu, G., Song, Q., Yuan, Q., and Kranias, E.G.:
Small
heat-shock protein Hsp20 phosphorylation inhibits beta-agonist-induced
cardiac apoptosis.
Circ.
Res. 94(11): 1474-82, 2004.
Song, Q., Young, K.B.,
Chu, G., Gulick, J., Gerst,
M., Grupp, I.L., Robbins, J., and Kranias E.G.:
Overexpression of phospholamban in slow-twitch skeletal muscle is associated
with depressed contractile function and muscle remodeling. FASEB
J. 18(9): 974-6, 2004.
Yatani, A., Kim, S. Kudej, R.K., Wang, Q., Depre, C.,
Irie, K., Kranais,
E.G., Vatner, S.F., and Vatner, D.E.:
Insights into cardioprotection obtained from study of cellular Ca2+ handling
in myocardium of true hibernating mammals. Am.
J. Physiology. 286(6):H2219-28, 2004.
Janczewski, A.M., Zahid, M., Lemster, B.H., Frye,
C., Gibson, G., Higuchi, Y., Kranias, E.G., Feldman, A.M., and McTiernan, C.F.: Phospholamban gene ablation improves calcium
transients but not cardiac function in a heart failure model. Cardiov. Res. 62(3):468-80, 2004.
Pan, Y., Kislinger, T., Gramolini, A.O., Zvaritch,
E., Kranias, E.G., MacLennan, D.H., and Emili, A.: Identification of biochemical adaptations in hyper-
or hypocontractile hearts from phospholamban
mutant mice by expression proteomics. PNAS
101:2241-46, 2004.
Braz, J.C., Gregory, K.,
Pathak, A., Sahin, B., Zhao, W.,
Jones, F., Klevitsky, R., Kimball, T.F., Lorenz,
J.N., Nairn, A.C., Liggett,
S.B., Bodi, I., Wang, S., Schwartz, A., Lakatta, E.G., DePaoli-Roach, A.A.,
Hewett, T.E., Bibb, J.A., Westfall, M.V., Kranias,
E.G., and Molkentin, J.D.: PKC alpha regulates
cardiac contractility and propensity towards heart failure. Nature
Med. 10(3):248-54, 2004.
*Gregory, K.N., *Hahn,
H., Haghighi, K., Marreez, Y., Odley,
A., **Kranias, E.G., and **Dorn, G.W.: Increased particulate partitioning
of PKC reverses susceptibility of phospholamban knockout hearts to ischemic
injury. J.
Mol. Cell. Cardiol. 36:313-18, 2004.
*Both authors contributed equally. **Both senior authors contributed equally.
Chu, G., Egnaczyk, G.F., Zhao, W., Gerst,
M., Maggio, J.E., and Kranias, E.G.: Phosphoproteome
-adrenergic stimulation: identificationbanalysis of cardiomyocytes subjected to and
characterization of a cardiac heat shock protein p20. Circ.
Res. 94:184-93, 2004.
Engelhardt, S., Hein, L., Kranias,
E.G., and Lohse, M.J.: Altered calcium handling
is critically involved in the cardiotoxic effects of chronic beta-adrenergic
stimulation. Circulation. 109(9):1154-60, 2004.
Invited Articles:
MacLennan, D.H. and Kranias, E.G.:
Regulation of the Sarco(endo)plasmic Reticulum Ca2+-ATPase
by Phospholamban and Sarcolipin. In: Handbook of ATPases, pp. 25-62 (Futei,
M., Wada, Y., Kaplan, J.H., eds.), 2004.
Zhao, W., Qiujing, S., and Kranias,
E.G.: The critical role of phospholamban in cardiac function. Hellenic
J. Cardiol. 45: 208-217, 2004.
Haghighi, K., Gregory, K.N., and
Kranias, E.G.: Sarcoplasmic reticulum calcium ATPase -phospholamban
interaction and cardiovascular disease. Biochem. Biophys. Res. Commun.
322(4):1214-1222, 2004.
Haghighi, K., Gregory, K.N., and
Kranias, E.G.: Phospholamban and Heart Failure. Journal of Heart
Failure 1(3): 159-166, 2004.
Sutliff, R.L., Conforti, L., Weber,
C., Kranias, E.G., and Paul, R.J.: Regulation of the spontaneous
contractile activity of the portal vein by the sarcoplasmic reticulum:
Evidence from the phospholamban gene-ablated mouse. Vascular Pharmacology
41(6):197-204, 2004.
2003
MacLennan DH, Kranias
EG. Phospholamban: a crucial regulator of cardiac contractility. Nat
Rev Mol Cell Biol. 2003 Jul;4(7):566-77. Review.
Schmidt AG, Haghighi
K, Frank B, Pater L, Dorn GW, Walsh RA, Kranias EG. Polymorphic SERCA2a
variants do not account for inter-individual differences in phospholamban-SERCA2a
interactions in human heart failure. J
Mol Cell Cardiol. 2003 Jul;35(7):867-70.
Said M, Vittone L, Mundina-Weilenmann
C, Ferrero P, Kranias E, Mattiazzi A. Role of dual site phospholamban
phosphorylation in the stunned heart: Insights from phospholamban-site
specific mutants. Am
J Physiol Heart Circ Physiol. 2003 May 22
Haghighi K, Kolokathis
F, Pater L, Lynch RA, Asahi M, Gramolini AO, Fan GC, Tsiapras D, Hahn
HS, Adamopoulos S, Liggett SB, Dorn GW 2nd, MacLennan DH, Kremastinos
DT, Kranias EG. Human phospholamban null results in lethal dilated cardiomyopathy
revealing a critical difference between mouse and human. J
Clin Invest. 2003 Mar;111(6):869-76.
Song Q, Schmidt AG, Hahn
HS, Carr AN, Frank B, Pater L, Gerst M, Young K, Hoit BD, McConnell BK,
Haghighi K, Seidman CE, Seidman JG, Dorn GW 2nd, Kranias EG. Rescue of
cardiomyocyte dysfunction by phospholamban ablation does not prevent ventricular
failure in genetic hypertrophy. J Clin
Invest. 2003 Mar;111(6):859-67.
Brittsan AG, Ginsburg
KS, Chu G, Yatani A, Wolska BM, Schmidt AG, Asahi M, MacLennan DH, Bers
DM, Kranias EG. Chronic SR Ca2+-ATPase inhibition causes adaptive changes
in cellular Ca2+ transport. Circ
Res. 2003 Apr 18;92(7):769-76. Epub 2003 Mar 13.
Sato Y, Schmidt AG, Kiriazis
H, Hoit BD, Kranias EG. Compensated hypertrophy of cardiac ventricles
in aged transgenic FVB/N mice overexpressing calsequestrin. Mol
Cell Biochem. 2003 Jan;242(1-2):19-25.
Dash R, Schmidt AG, Pathak
A, Gerst MJ, Biniakiewicz D, Kadambi VJ, Hoit BD, Abraham WT, Kranias
EG. Differential regulation of p38 mitogen-activated protein kinase mediates
gender-dependent catecholamine-induced hypertrophy. Cardiovasc
Res. 2003 Mar;57(3):704-14.
Schmitt JP, Kamisago
M, Asahi M, Li GH, Ahmad F, Mende U, Kranias EG, MacLennan DH, Seidman
JG, Seidman CE. Dilated cardiomyopathy and heart failure caused by a mutation
in phospholamban. Science.
2003 Feb 28;299(5611):1410-3.
Chu G, Haghighi K, Kranias
EG. From mouse to man: understanding heart failure through genetically
altered mouse models. J
Card Fail. 2002 Dec;8(6 Suppl):S432-49.
Isoda T, Paolocci N,
Haghighi K, Wang C, Wang Y, Georgakopoulos D, Servillo G, Della Fazia
MA, Kranias EG, Depaoli-Roach AA, Sassone-Corsi P, Kass DA. Novel regulation
of cardiac force-frequency relation by CREM (cAMP response element modulator).
FASEB
J. 2003 Feb;17(2):144-51.
Zhao W, Frank KF, Chu
G, Gerst MJ, Schmidt AG, Ji Y, Periasamy M, Kranias EG. Combined phospholamban
ablation and SERCA1a overexpression result in a new hyperdynamic cardiac
state. Cardiovasc
Res. 2003 Jan;57(1):71-81.
Invited Articles:
Sato, Y., Schmidt, A.G., Kiriazis,
H., Hoit, B.D., and Kranias, E.G.: Compensated hypertrophy of cardiac
ventricles in aged transgenic FVB/N mice overexpressing calsequestrin.
Molec. & Cellular Biochem. 242: 19-25, 2003.
Dash, R. and Kranias, E.G.:
The contractile and neurohoromonal roles of phospholamban in heart failure.
In: Cardiac Remodeling and Failure, pp. 135-152, (P.K. Singal, I.M.C.
Dixon, L.A. Kirshenbaum and N.S. Dhalla), Kluwer Academic Publishers,
2003.
MacLennan, D.H. and Kranias, E.G.: Phospholamban: a crucial regulator of cardiac contractility.
Nat Rev Mol Cell Biol. 4(7): 566-77, 2003.
Mitton, B, and Kranias, E.G.:
Proteomics: its potential in the Post-Genome. Hellenic J Cardiol. 44:
301-307, 2003.
2002
Brixius K, Savvidou-Zaroti
P, Mehlhorn U, Bloch W, Kranias EG, Schwinger RH. Increased Ca2+-sensitivity
of myofibrillar tension in heart failure and its functional implication.
Basic
Res Cardiol. 2002;97 Suppl 1:I111-7.
Frank KF, Bolck B, Brixius
K, Kranias EG, Schwinger RH. Modulation of SERCA: implications for the
failing human heart. Basic
Res Cardiol. 2002;97 Suppl 1:I72-8.
Chu G, Kranias EG. Functional
interplay between dual site phospholambam phosphorylation: insights from
genetically altered mouse models. Basic
Res Cardiol. 2002;97 Suppl 1:I43-8.
Schmidt AG, Zhai J, Carr
AN, Gerst MJ, Lorenz JN, Pollesello P, Annila A, Hoit BD, Kranias EG.
Structural and functional implications of the phospholamban hinge domain:
impaired SR Ca2+ uptake as a primary cause of heart failure. Cardiovasc
Res. 2002 Nov;56(2):248-59.
Cross HR, Kranias EG,
Murphy E, Steenbergen C. Ablation of PLB exacerbates ischemic injury to
a lesser extent in female than male mice: protective role of NO. Am J
Physiol Heart Circ Physiol. 2003
Feb;284(2):H683-90. Epub 2002 Oct 03.
Schmidt AG, Gerst M,
Zhai J, Carr AN, Pater L, Kranias EG, Hoit BD. Evaluation of left ventricular
diastolic function from spectral and color M-mode Doppler in genetically
altered mice. J Am Soc Echocardiogr. 2002
Oct;15(10 Pt 1):1065-73.
Carr AN, Kranias EG.
Thyroid hormone regulation of calcium cycling proteins. Thyroid.
2002 Jun;12(6):453-7.
Paul RJ, Shull GE, Kranias
EG. The sarcoplasmic reticulum and smooth muscle function: evidence from
transgenic mice. Novartis
Found Symp. 2002;246:228-38; discussion 238-43, 272-6.
Chu G, Carr AN, Young
KB, Lester JW, Yatani A, Sanbe A, Colbert MC, Schwartz SM, Frank KF, Lampe
PD, Robbins J, Molkentin JD, Kranias EG. Enhanced myocyte contractility
and Ca2+ handling in a calcineurin transgenic model of heart failure.
Cardiovasc
Res. 2002 Apr;54(1):105-16.
Carr AN, Schmidt AG,
Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB,
Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA,
Kranias EG. Type 1 phosphatase, a negative regulator of cardiac function.
Mol
Cell Biol. 2002 Jun;22(12):4124-35.
Wolska BM, Arteaga GM,
Pena JR, Nowak G, Phillips RM, Sahai S, de Tombe PP, Martin AF, Kranias
EG, Solaro RJ. Expression of slow skeletal troponin I in hearts of phospholamban
knockout mice alters the relaxant effect of beta-adrenergic stimulation.
Circ
Res. 2002;90:882-8.
Pi Y, Kemnitz KR, Zhang
D, Kranias EG, Walker JW. Phosphorylation of troponin I controls cardiac
twitch dynamics: evidence from phosphorylation site mutants expressed
on a troponin I- null background in mice. Circ
Res. 2002;90:649-56.
Li Y, Kranias EG, Mignery GA, Bers DM. Protein kinase
A phosphorylation of the ryanodine receptor does not affect calcium sparks
in mouse ventricular myocytes. Circ
Res. 2002;90:309-16.
Kiriazis H, Sato Y, Kadambi
VJ, Schmidt AG, Gerst MJ, Hoit BD, Kranias EG. Hypertrophy and functional
alterations in hyperdynamic phospholamban- knockout mouse hearts under
chronic aortic stenosis. Cardiovasc
Res. 2002;53:372-81.
Chu G, Carr AN, Young
KB, Lester JW, Yatani A, Sanbe A, Colbert MC, Schwartz SM, Frank KF, Lampe
PD, Robbins J, Molkentin JD, Kranias EG. Enhanced myocyte contractility
and Ca(2+) handling in a calcineurin transgenic model of heart failure.
Cardiovasc
Res. 2002;54:105-16.
Carr AN, Schmidt AG,
Suzuki Y, del Monte F, Sato Y, Lanner C, Breeden K, Jing SL, Allen PB,
Greengard P, Yatani A, Hoit BD, Grupp IL, Hajjar RJ, DePaoli-Roach AA,
Kranias EG. Type 1 phosphatase, a negative regulator of cardiac function.
Mol
Cell Biol. 2002;22:4124-35.
Invited Articles:
Paul, R.J., Shull, G.E. and Kranias,
E.G.: The sarcoplasmic reticulum and smooth muscle function: evidence
from transgenic mice. In: Role of the sarcoplasmic reticulum in smooth
muscle, pp. 228-243, (Wiley, Chichester: Novartis Symposium No. 246), 2002.
Chu, G. and Kranias, E.G.: Functional interplay
between dual site phospholamban phosphorylation: Insights from genetically
altered mouse models. Basic Res. Cardiol. 97, Suppl. 1: 1/43-1/48, 2002.
Frank, K.F., Bolck, B., Brixius,
K., Kranias, E.G., and Schwinger, R.H.G.: Modulation of SERCA:
Implications for the failing human heart. Basic Res. Cardiol. 97, Suppl.
1: 1/72-1/78, 2002.
Carr, A.N. and Kranias, E.G.:
Thyroid hormone regulation of calcium cycling proteins. In: Thyroid 12,
453-457, 2002.
Chu, G., Haghighi, K. and Kranias, E.G.: From
mouse to man: Understanding heart failure through genetically altered
mouse models. In: Journal of Cardiac Failure 8(6 Suppl): S432-S449, 2002.
Pathak, A. and Kranias, E.G.: The role of molecular biology in
medicine: new horizons in the 21st century. Archives of Hellenic
Medicine 19(5): 497-503, 2002.
2001
Slack JP, Grupp IL, Dash
R, Holder D, Schmidt A, Gerst MJ, Tamura T, Tilgmann C, James PF, Johnson
R, Gerdes AM, Kranias EG. The enhanced contractility of the phospholamban-deficient
mouse heart persists with aging. J
Mol Cell Cardiol. 2001;33:1031-40.
Shannon TR, Chu G, Kranias
EG, Bers DM. Phospholamban decreases the energetic efficiency of the sarcoplasmic
reticulum Ca pump. J
Biol Chem. 2001;276:7195-201.
Schmidt AG, Edes I, Kranias
EG. Phospholamban: a promising therapeutic target in heart failure? Cardiovasc
Drugs Ther. 2001;15:387-96.
Sato Y, Kiriazis H, Yatani
A, Schmidt AG, Hahn H, Ferguson DG, Sako H, Mitarai S, Honda R, Mesnard-Rouiller
L, Frank KF, Beyermann B, Wu G, Fujimori K, Dorn GW, 2nd, Kranias EG.
Rescue of contractile parameters and myocyte hypertrophy in calsequestrin
overexpressing myocardium by phospholamban ablation. J
Biol Chem. 2001;276:9392-9.
Sato Y, Schmidt AG, Kiriazis
H, Hoit BD, Kranias EG. Letter to the editor: Re-evaluation of heart failure
in transgenic mice with impaired SR Ca2+ release. J
Mol Cell Cardiol. 2001;33:1757-9.
Nobe K, Sutliff RL, Kranias
EG, Paul RJ. Phospholamban regulation of bladder contractility: evidence
from gene- altered mouse models. J
Physiol. 2001;535:867-78.
Haghighi K, Schmidt AG,
Hoit BD, Brittsan AG, Yatani A, Lester JW, Zhai J, Kimura Y, Dorn GW,
2nd, MacLennan DH, Kranias EG. Superinhibition of sarcoplasmic reticulum
function by phospholamban induces cardiac contractile failure. J
Biol Chem. 2001;276:24145-52.
Freeman K, Lerman I,
Kranias EG, Bohlmeyer T, Bristow MR, Lefkowitz RJ, Iaccarino G, Koch WJ,
Leinwand LA. Alterations in cardiac adrenergic signaling and calcium cycling
differentially affect the progression of cardiomyopathy. J
Clin Invest. 2001;107:967-74.
Frank KF, Mesnard-Rouiller
L, Chu G, Young KB, Zhao W,
Haghighi K, Sato Y, Kranias EG. Structure and expression of the mouse
cardiac calsequestrin gene. Basic Res Cardiol. 2001;96:636-44.
Dash R, Kadambi V, Schmidt
AG, Tepe NM, Biniakiewicz D, Gerst MJ, Canning AM, Abraham WT, Hoit BD,
Liggett SB, Lorenz JN, Dorn GW, 2nd, Kranias EG. Interactions between
phospholamban and beta-adrenergic drive may lead to cardiomyopathy and
early mortality. Circulation.
2001;103:889-96.
Dash R, Frank KF, Carr
AN, Moravec CS, Kranias EG. Gender influences on sarcoplasmic reticulum
Ca2+-handling in failing human myocardium. J
Mol Cell Cardiol. 2001;33:1345-53.
Carr AN, Sutliff RL,
Weber CS, Allen PB, Greengard P, de Lanerolle P, Kranias EG, Paul RJ.
Is myosin phosphatase regulated in vivo by inhibitor-1? Evidence from
inhibitor-1 knockout mice. J
Physiol. 2001;534:357-66.
Aronow BJ, Toyokawa T,
Canning A, Haghighi K, Delling U, Kranias E, Molkentin JD, Dorn GW, 2nd.
Divergent transcriptional responses to independent genetic causes of cardiac
hypertrophy. Physiol
Genomics. 2001;6:19-28.
Invited Articles:
Brittsan, A.G. and Kranias, E.G.:
Phospholamban and cardiac contractile function. J. Mol. Cell. Cardiol.
32, 2131-2139, 2000.
Schmidt, A.G., Kadambi, V.J., Young,
K.B. and Kranias, E.G.: Genetic alterations and modeling of cardiovascular
physiology. In: Cardiovascular Physiology in the Genetically Engineered
Mouse, pp. 17-38 (Hoit, B.D. and Walsh, R.A.), Kluwer Academic Publishers,
Norwell, MA, 2001.
39Schmidt, A.G., Edes, I. and Kranias, E.G.: Phospholamban: a promising
therapeutic target in heart failure. In: Cardiovascular Drugs and Therapy,
pp. 387-396 (Opie, L.H. and Remme, W.J., eds.), 2001.
2000
Zvaritch E, Backx PH,
Jirik F, Kimura Y, de Leon S, Schmidt AG, Hoit BD, Lester JW, Kranias
EG, MacLennan DH. The transgenic expression of highly inhibitory monomeric
forms of phospholamban in mouse heart impairs cardiac contractility. J
Biol Chem. 2000;275:14985-91.
Zhai J, Schmidt
AG, Hoit BD, Kimura Y, MacLennan DH, Kranias EG. Cardiac-specific overexpression
of a superinhibitory pentameric phospholamban mutant enhances inhibition
of cardiac function in vivo. J
Biol Chem. 2000;275:10538-44.
Schwinger RH, Brixius
K, Savvidou-Zaroti P, Bolck B, Zobel C, Frank K, Kranias EG, Hoischen
S, Erdmann E. The enhanced contractility in phospholamban deficient mouse
hearts is not associated with alterations in (Ca2+)-sensitivity or myosin
ATPase- activity of the contractile proteins. Basic
Res Cardiol. 2000;95:12-8.
Schmidt AG, Kadambi
VJ, Ball N, Sato Y, Walsh RA, Kranias EG, Hoit BD. Cardiac-specific overexpression
of calsequestrin results in left ventricular hypertrophy, depressed force-frequency
relation and pulsus alternans in vivo. J
Mol Cell Cardiol. 2000;32:1735-44.
Li L, Desantiago
J, Chu G, Kranias EG, Bers DM. Phosphorylation of phospholamban and troponin
I in beta-adrenergic- induced acceleration of cardiac relaxation. Am
J Physiol Heart Circ Physiol. 2000;278:H769-79.
Kranias EG. Commentary
on the special topic section on the use of transgenic models. Annu
Rev Physiol. 2000;62:965-9.
Kiriazis H, Kranias
EG. Genetically engineered models with alterations in cardiac membrane
calcium-handling proteins. Annu
Rev Physiol. 2000;62:321-51.
Hoit BD, Kadambi
VJ, Tramuta DA, Ball N, Kranias EG, Walsh RA. Influence of sarcoplasmic
reticulum calcium loading on mechanical and relaxation restitution. Am
J Physiol Heart Circ Physiol. 2000;278:H958-63.
Frank K, Tilgmann
C, Shannon TR, Bers DM, Kranias
EG. Regulatory role of phospholamban in the efficiency of cardiac sarcoplasmic
reticulum Ca2+ transport. Biochemistry. 2000;39:14176-82.
Frank K, Kranias
EG. Phospholamban and cardiac contractility. Ann
Med. 2000;32:572-8.
Chu G, Lester JW,
Young KB, Luo W, Zhai J, Kranias EG. A single site (Ser16) phosphorylation
in phospholamban is sufficient in mediating its maximal cardiac responses
to beta -agonists. J
Biol Chem. 2000;275:38938-43.
Brittsan AG, Carr AN,
Schmidt AG, Kranias EG. Maximal inhibition of SERCA2 Ca(2+) affinity by
phospholamban in transgenic hearts overexpressing a non-phosphorylatable
form of phospholamban. J
Biol Chem. 2000;275:12129-35.
Brittsan AG, Kranias
EG. Phospholamban and cardiac contractile function. J
Mol Cell Cardiol. 2000;32:2131-9.
Bluhm WF, Kranias EG,
Dillmann WH, Meyer M. Phospholamban: a major determinant of the cardiac
force-frequency relationship. Am
J Physiol Heart Circ Physiol. 2000;278:H249-55
Invited Articles:
Kiriazis, H. and Kranias, E.G.:
Genetically Engineered Models with alterations in cardiac membrane calcium-handling
proteins. Annu. Rev. Physiol. 62:321-351, 2000.
Schmidt, A. and Kranias, E.G.:
Genetic Approaches to Elucidate the regulatory role of phospholamban in
the heart. In: “Molecular Approaches to the Therapy of Heart Failure”,
pp. 39-52 (G. Hasenfuss and E. Marban) Steinkopff, Darmstadt and Springer Publishers, 2000.
Edes, I. and Kranias, E.G.: Ca2+-ATPases.
In: Cell Physiology (N. Sperelakis,
ed.), Academic Press, San
Diego, 2000.
Edes, I., Chu, X. and
Kranias, E.G.: Sarcoplasmic Reticulum Calcium Transport. In:
Heart Physiology and Pathophysiology, pp 447-460. (N. Sperelakis, Y. Kurachi, A. Terzic and M. Cohen, eds.), Academic Press,
San Diego, 2000.
Frank, K. and Kranias, E.G.:
Phospholamban and Cardiac Contractility. In: Annals of Medicine (The
Finnish Med. Soc. Duodecim) 32: 572-578, 2000.
|
|
Kranias Lab
Research
Topics
Heart Failure
Cardiac Function
The Sarcoplasmic Reticulum
Phospholamban
SERCA
Calsequestrin
HRC
Junctin
HAX-1
Heat Shock Proteins
Protein Phosphate 1 Inhibitor-1
Proteomics & Phosphoproteomics
Transgenic Rabbits
Human SR Genetic Variations
Lab home
|
